|
|
Article: Drugmaker readies son of Claritin; New Schering-Plough allergy drug will likely bear the Clarinex name.(Brief Article)
- Article from:
- Advertising Age
- Article date:
- August 7, 2000
- Author:
CopyrightCOPYRIGHT 2000 Crain Communications, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Schering-Plough's Corp.'s so-called son of Claritin will resemble its predecessor quite a bit. Schering-Plough hopes to dub the blockbuster allergy drug's successor Clarinex, according to people familiar with the matter. Schering-Plough is awaiting approval from the U.S. Food & Drug Administration on the new drug, which could come this fall. The company is also waiting for FDA clearance to use the name Clarinex. A company spokesman declined to comment. By choosing a name similar to Claritin, Schering-Plough hopes to capitalize on the near-ubiquitous physician and consumer recognition of Claritin as it markets the drug's successor. Some industry observers, however, ...
Related newspaper, magazine, and journal articles:
|
|
Article: IMPAX Comments On Schering Lawsuit Related to Generic ...
Business Wire;
February 1, 2001 ;
700+ words
... ... ANDA) for a generic version of Claritin(R) (loratadine) Reditabs. Schering markets Claritin Reditabs for the relief of symptoms ... its product does not infringe Schering's listed patents on Claritin Reditabs. "We are not surprised ...
|
|